Biochemotaxis‐Oriented Engineering Bacteria Expressing GLP‐1 Enhance Diabetes Therapy by Regulating the Balance of Immune
Advanced Healthcare Materials · 2024-04 · 13 (11)
DOI: 10.1002/adhm.202303958 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Healthcare Materials, online erschienen am 11.02.2024. Verfasst von Yifei Wang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China. Hauptthemen laut MEDLINE: Glucagon-Like Peptide 1, Escherichia coli. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 59 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Excellent Youth Science Foundation of Henan province, Training program for young key teachers in Henan Province.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Glucagon like peptide‐1 (GLP‐1) is an effective hypoglycemic drug that can repair the pancreas β cells and promote insulin secretion. However, GLP‐1 has poor stability and lacks of target ability, which makes it difficult to reach the site of action to exert its efficacy. Here, GLP‐1‐expressing plasmids are introduced into the Escherichia coli Nissle 1917 (EcN) and a lipid membrane is formed through simple self‐assembly on its surface, resulting in an oral delivery system (LEG) capable of resisting the harsh environment of the gastrointestinal tract. The system utilizes the chemotactic properties of probiotics to achieve efficient enrichment at the pancreatic site, and protects islet β cells from destruction by regulating the balance of immune cells. More interestingly, LEG not only continuously produces GLP‐1 to restore pancreatic islet β cell function and secrete insulin to control blood sugar levels, but also regulates the intestinal flora and increases the richness and diversity of probiotics. In mice diabetes models, oral administration of LEG only once every other day has good biosafety and compliance, and achieves long‐term control of blood glucose. Therefore, this strategy not only provides an oral delivery platform for pancreatic targeting, but also opens up new avenues for reversing diabetes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of MRI, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, 450052, China.
- School of Pharmaceutical Sciences, Zhengzhou University, Zhengzhou, 450001, China.
- Key Laboratory of Targeting Therapy and Diagnosis for Critical Diseases, Zhengzhou University, Zhengzhou, 450001, China.
ORCID-Profile: Zhenzhong Zhang
Förderung
- National Natural Science Foundation of China
- Excellent Youth Science Foundation of Henan province
- Training program for young key teachers in Henan Province
Zitieren
APA
Wang, Y., Shi, Y., Peng, X., Li, T., Liang, C., Wang, W., Zhou, M., Yang, J., Cheng, J., Zhang, Z., & Hou, L. (2024). Biochemotaxis‐Oriented Engineering Bacteria Expressing GLP‐1 Enhance Diabetes Therapy by Regulating the Balance of Immune. Advanced Healthcare Materials, 13(11). https://doi.org/10.1002/adhm.202303958
Vancouver
Wang Y, Shi Y, Peng X, Li T, Liang C, Wang W, et al. Biochemotaxis‐Oriented Engineering Bacteria Expressing GLP‐1 Enhance Diabetes Therapy by Regulating the Balance of Immune. Advanced Healthcare Materials. 2024;13(11). doi:10.1002/adhm.202303958
BibTeX
@article{Wang2024,
author = {Wang, Yifei and Shi, Yupeng and Peng, Xueyuan and Li, Tongtong and Liang, Chenglin and Wang, Wenhao and Zhou, Mengyang and Yang, Jiali and Cheng, Jingliang and Zhang, Zhenzhong and Hou, Lin},
title = {Biochemotaxis‐Oriented Engineering Bacteria Expressing GLP‐1 Enhance Diabetes Therapy by Regulating the Balance of Immune},
journal = {Advanced Healthcare Materials},
year = {2024},
volume = {13},
number = {11},
doi = {10.1002/adhm.202303958}
}
EUVIMED